Derendorf H, Hochhaus G, Rohatagi S, Möllmann H, Barth J, Sourgens H, Erdmann M
Department of Pharmaceutics, University of Florida, Gainesville, USA.
J Clin Pharmacol. 1995 Mar;35(3):302-5. doi: 10.1002/j.1552-4604.1995.tb04064.x.
The pharmacokinetics of triamcinolone acetonide were studied after intravenous (2 mg), oral (5 mg), and inhaled (2 mg) administration. Triamcinolone acetonide concentrations were measured in plasma by high-performance liquid chromatography/radioimmunoassay. After intravenous administration, triamcinolone acetonide was eliminated with a total body clearance of 37 L/h and a half-life of 2.0 hours. The volume of distribution was 103 L, and oral bioavailability averaged 23%. Absorption was rapid, achieving maximum triamcinolone acetonide levels of 10.5 ng/mL after 1 hour. After inhalation, bioavailability averaged 22% with maximum levels of 2.0 ng/mL observed after 2.1 hours. The resulting systemic levels for all three treatments caused a significant decrease in the number of lymphocytes in blood.